Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cranford Scott

Internal Medicine Inglewood, CA Medical Doctor

NPI 1265437925 CMS profile 328844

233 N Prairie Ave, Inglewood, CA 90301

Open in the dashboard

General payments

$7,797

287 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$920 paid to institutions, not to them · program year 2019

Through program year 2025, Cranford Scott of Inglewood, CA is reported in the CMS Open Payments database as having received $7,797 across 287 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $920 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 93rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,485 27
2024 General $901 23
2023 General $1,057 35
2022 General $1,062 44
2021 General $1,244 52
2020 General $951 52
2019 General $1,096 54

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cranford Scott
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Cranford Scott were reported at $1,485. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Cranford Scott Internal Medicine median Middle half National median
2019 $1,096 $159 $48–$570 $163
2020 $951 $119 $33–$402 $114
2021 $1,244 $135 $37–$521 $132
2022 $1,062 $141 $42–$496 $149
2023 $1,057 $149 $45–$519 $160
2024 $901 $154 $47–$537 $164
2025 $1,485 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $970 37 payments
  2. Amgen Inc. $954 21 payments
  3. AstraZeneca Pharmaceuticals LP $686 19 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $678 27 payments
  5. Lilly USA, LLC $505 17 payments
  6. Sanofi-Aventis U.S. LLC $410 15 payments
  7. Electromed, Inc. $368 1 payment
  8. Arbor Pharmaceuticals, Inc. $324 22 payments
  9. Janssen Pharmaceuticals, Inc $323 12 payments
  10. Pfizer Inc. $299 16 payments
  11. Other $2,279 100 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,792 286 payments
  2. Education $4 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $734 30 payments
  2. Ozempic $685 32 payments
  3. EVENITY $684 7 payments
  4. Kerendia $678 27 payments
  5. SMARTVEST $368 1 payment
  6. FARXIGA $361 13 payments
  7. MOUNJARO $324 9 payments
  8. XARELTO $323 12 payments
  9. NEXLETOL $267 8 payments
  10. PRALUENT $232 6 payments
  11. Other $4,155 190 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 101 drugs

Part D claims

4,089

Median for Internal Medicine: 777

Drug cost

$630,533

Median for Internal Medicine: $73,373

Branded share of claims

25.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Rybelsus Semaglutide Brand 122 $164,104
Ozempic Semaglutide Brand 68 $88,944
Jardiance Empagliflozin Brand 81 $78,641
Mounjaro Tirzepatide Brand 29 $39,627
Eliquis Apixaban Brand 37 $38,948
Trulicity Dulaglutide Brand 33 $34,697
Cinacalcet Hcl Generic 13 $17,929
Tresiba Flextouch U-100 Insulin Degludec Brand 30 $16,202
Farxiga Dapagliflozin Propanediol Brand 14 $14,267
Nebivolol Hcl Generic 145 $12,833

The 10 drugs with the highest cost, of 101 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 23 billing codes

Paid by Medicare

$110,512

Medicare's payments for the services billed

Medicare patients

212

Average age 74

Services billed

1,739

145 women, 67 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 63%
Diabetes 62%
Ischemic heart disease 37%
Depression 37%
Chronic kidney disease 36%
Heart failure 26%
COPD 22%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $268
$268 — —
MOUNJARO
  • Lilly USA, LLC $165
$165 29 —
MAVYRET
  • AbbVie, Inc. $125
$125 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $103
$103 — —
AFREZZA
  • Mannkind Corporation $71
$71 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

287 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record